Observed and relative survival trends of lung cancer: A systematic review of population-based cancer registration data
- PMID: 37986711
- PMCID: PMC10788469
- DOI: 10.1111/1759-7714.15170
Observed and relative survival trends of lung cancer: A systematic review of population-based cancer registration data
Abstract
Background: Using the published survival statistics from cancer registration or population-based studies, we aimed to describe the global pattern and trend of lung cancer survival.
Methods: By searching SinoMed, PubMed, Web of Science, EMBASE, and SEER, all survival analyses from cancer registration or population-based studies of lung cancer were collected by the end of November 2022. The survival rates were extracted by sex, period, and country. The observed, relative, and net survival rates of lung cancer were applied to describe the pattern and time changes from the late 1990s to the early 21st century.
Results: Age-standardized 5-year relative/net survival rate of lung cancer was typically low, with 10%-20% for most regions. The highest age-standardized relative/net survival rate was observed in Japan (32.9%, 2010-2014), and the lowest was in India (3.7%, 2010-2014). In most countries, the five-year age-standardized relative/net survival rates of lung cancer were higher in females and younger people. The patients with adenocarcinoma had a better prognosis than other groups. In China, the highest 5-year overall relative/net survival rates were 27.90% and 31.62% in men and women in Jiangyin (2012-2013).
Conclusion: Over the past decades, the prognosis of lung cancer has gradually improved, but significant variations were also observed globally. Worldwide, a better prognosis of lung cancer can be observed in females and younger patients. It is essential to compare and evaluate the histological or stage-specific survival rates of lung cancer between different regions in the future.
Keywords: cancer registry; lung cancer; observed survival rate; population-based survival study; relative survival rate.
© 2023 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
Conflict of interest statement
All authors declare there are no conflicts of interest.
Figures
References
-
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. - PubMed
-
- Cancer Hospital Chinese Academy of Medical Science . Chinese guideline for cancer registration. Beijing: People's Medical Publishing House (PMPH); 2016. p. 33–75.
-
- Hakulinen T. Cancer survival corrected for heterogeneity in patient withdrawal. Biometrics. 1982;38(4):933–942. - PubMed
-
- Perme MP, Stare J, Estève J. On estimation in relative survival. Biometrics. 2012;68(1):113–120. - PubMed
-
- Hakulinen T, Seppä K, Lambert PC. Choosing the relative survival method for cancer survival estimation. Eur J Cancer. 2011;47(14):2202–2210. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
